NCT02097758 Efficacy of Three Dimensional Transesophageal Echocardiography for Percutaneous Device Closure in Atrial Septal Defect
| NCT ID | NCT02097758 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Asan Medical Center |
| Condition | Atrial Septal Defect |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2014-03 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2014-03 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Background: Three-dimensional echocardiographic image for atrial septal defect (ASD) is useful for evaluation of defect size and shape. The investigators suggested optimal device size using three-dimensional transesophageal echocardiographic image and our formula in previous study. Purpose: In this study, the investigators seek to predict the correct device size and confirm the accuracy of the formula that we made before device closure in ASD patients.
Eligibility Criteria
Inclusion Criteria: * Age ≥18 year-old * Susceptible indication for atrial septal defect closure * Potential candidate for device closure Exclusion Criteria: * Poor candidate for device closure: multiple ASDs, ect * Other heart disease requiring open heart surgery
Contact & Investigator
Jong-Min Song, MD PhD
PRINCIPAL INVESTIGATOR
Asan Medical Center
Frequently Asked Questions
Who can join the NCT02097758 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Atrial Septal Defect. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02097758 currently recruiting?
Yes, NCT02097758 is actively recruiting participants. Contact the research team at jmsong@amc.seoul.kr for enrollment information.
Where is the NCT02097758 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT02097758 clinical trial?
NCT02097758 is sponsored by Asan Medical Center. The principal investigator is Jong-Min Song, MD PhD at Asan Medical Center. The trial plans to enroll 100 participants.